Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation

AGID^1,2

April 2012

The importance of an early diagnosis of autoimmune gastrointestinal dysmotility lies in less morbidity with early treatment. Many of these patients have a favorable response to pyridostigmine which can improve synaptic transmission by inhibiting acetylcholinesterase. Many of these patients will improve with immunotherapies such as intravenous immunoglobulin or intravenous steroids, particularly if started early. Longer term therapy with immunosuppressants may be required if objective benefit is noted with the initial trial of therapy. Depending on the antibody or profile of antibodies detected, a search for cancer may be initiated on this basis. Sometimes particular antibodies detected or a profile of antibodies detected can help identify the histological type of cancer present, and thus guide, oncological investigations.

< Previous Slide

AGID1,2

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• AGID
• Symptoms
• AGID¹
• AGID^1,2
• AGID: Laboratory Findings
• AGID: Antibody Evaluation
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody^3,4
• Ganglionic AChR Autoantibody
• AGID Antibody Profile
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• Clinical Utility of AGID Evaluation
• Clinical Utility of AGID Evaluation
• Summary
• References
• Questions